WO2009098404A8 - Procédé de préparation de nanoparticules à base de molécules ou macromolécules amphiphiles fonctionnelles et leur utilisation - Google Patents

Procédé de préparation de nanoparticules à base de molécules ou macromolécules amphiphiles fonctionnelles et leur utilisation Download PDF

Info

Publication number
WO2009098404A8
WO2009098404A8 PCT/FR2008/001661 FR2008001661W WO2009098404A8 WO 2009098404 A8 WO2009098404 A8 WO 2009098404A8 FR 2008001661 W FR2008001661 W FR 2008001661W WO 2009098404 A8 WO2009098404 A8 WO 2009098404A8
Authority
WO
WIPO (PCT)
Prior art keywords
macromolecules
amphiphilic molecules
nanoparticles based
preparing nanoparticles
functional amphiphilic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2008/001661
Other languages
English (en)
Other versions
WO2009098404A3 (fr
WO2009098404A2 (fr
Inventor
Philippe Barthelemy
Michel Camplo
Nathalie Campins
Bruno Chauffert
Florence Bouyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aix Marseille Universite
Universite Victor Segalen Bordeaux 2
Universite de Bourgogne
Original Assignee
Universite Victor Segalen Bordeaux 2
Universite de la Mediterranee Aix Marseille II
Universite de Bourgogne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Victor Segalen Bordeaux 2, Universite de la Mediterranee Aix Marseille II, Universite de Bourgogne filed Critical Universite Victor Segalen Bordeaux 2
Priority to CN2008801260085A priority Critical patent/CN101932310B/zh
Priority to CA2706812A priority patent/CA2706812A1/fr
Priority to EP08872219A priority patent/EP2231132A2/fr
Priority to US12/745,670 priority patent/US20110059180A1/en
Priority to JP2010535425A priority patent/JP5719594B2/ja
Publication of WO2009098404A2 publication Critical patent/WO2009098404A2/fr
Publication of WO2009098404A3 publication Critical patent/WO2009098404A3/fr
Publication of WO2009098404A8 publication Critical patent/WO2009098404A8/fr
Anticipated expiration legal-status Critical
Priority to US14/208,978 priority patent/US9533049B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne un procédé de préparation de nanoparticules à base de molécules ou macromolécules amphiphiles fonctionnelles, éventuellement en présence d'au moins un colipide, permettant Pencapsulation d'agents thérapeutiques, en particulier d'agents anti-tumoraux, et leur utilisation pour le transport et la vectorisation d'agents thérapeutiques, en particulier d'agents anti-tumoraux.
PCT/FR2008/001661 2007-11-30 2008-11-28 Procédé de préparation de nanoparticules à base de molécules ou macromolécules amphiphiles fonctionnelles et leur utilisation Ceased WO2009098404A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN2008801260085A CN101932310B (zh) 2007-11-30 2008-11-28 制备基于官能两亲分子或者大分子的纳米颗粒的方法和其用途
CA2706812A CA2706812A1 (fr) 2007-11-30 2008-11-28 Procede de preparation de nanoparticules a base de molecules ou macromolecules amphiphiles fonctionnelles et leur utilisation
EP08872219A EP2231132A2 (fr) 2007-11-30 2008-11-28 Procédé de préparation de nanoparticules à base de molécules ou macromolécules amphiphiles fonctionnelles et leur utilisation
US12/745,670 US20110059180A1 (en) 2007-11-30 2008-11-28 Method for Preparing Nanoparticles Based on Functional Amphiphilic Molecules or Macromolecules, and the Use Thereof
JP2010535425A JP5719594B2 (ja) 2007-11-30 2008-11-28 機能性両親媒性の分子又は巨大分子を基とするナノ粒子の調製方法及びその使用
US14/208,978 US9533049B2 (en) 2007-11-30 2014-03-13 Method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, and the use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR07/08399 2007-11-30
FR0708399A FR2924430B1 (fr) 2007-11-30 2007-11-30 Procede de preparation de nanoparticules a base de molecules ou macromolecules amphiphiles fonctionnelles et leur utilisation

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/745,670 A-371-Of-International US20110059180A1 (en) 2007-11-30 2008-11-28 Method for Preparing Nanoparticles Based on Functional Amphiphilic Molecules or Macromolecules, and the Use Thereof
US14/208,978 Division US9533049B2 (en) 2007-11-30 2014-03-13 Method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, and the use thereof

Publications (3)

Publication Number Publication Date
WO2009098404A2 WO2009098404A2 (fr) 2009-08-13
WO2009098404A3 WO2009098404A3 (fr) 2009-11-12
WO2009098404A8 true WO2009098404A8 (fr) 2010-01-28

Family

ID=39638675

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2008/001661 Ceased WO2009098404A2 (fr) 2007-11-30 2008-11-28 Procédé de préparation de nanoparticules à base de molécules ou macromolécules amphiphiles fonctionnelles et leur utilisation

Country Status (7)

Country Link
US (2) US20110059180A1 (fr)
EP (1) EP2231132A2 (fr)
JP (3) JP5719594B2 (fr)
CN (1) CN101932310B (fr)
CA (1) CA2706812A1 (fr)
FR (1) FR2924430B1 (fr)
WO (1) WO2009098404A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2945946B1 (fr) * 2009-05-29 2011-08-26 Univ Victor Segalen Bordeaux 2 Formulations a compartiments multiples a base de molecules ou macromolecules amphiphiles fonctionnelles
ES2660752T3 (es) * 2014-10-06 2018-03-26 Universite de Bordeaux Compuestos de bola-anfifílicos y sus usos para aplicaciones biomédicas
EP3085360A1 (fr) * 2015-04-20 2016-10-26 Universite De Bordeaux Compositions de nanovecteurs à base de lipide chargées avec des nanoparticules métalliques et agent thérapeutique
WO2018035380A1 (fr) 2016-08-17 2018-02-22 Solstice Biologics, Ltd. Constructions polynucléotidiques
WO2019006455A1 (fr) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. Auxiliaires de phosphoramidites chiraux et leurs procédés d'utilisation
EP3502684A1 (fr) 2017-12-22 2019-06-26 Universite De Bordeaux Procédé de détection d'ions métalliques dans des solutions aqueuses au moyen de composés nucléolipides
EP3505178A1 (fr) 2017-12-29 2019-07-03 Universite De Bordeaux Formulations de gel de bio-encres comprenant un composé à base de nucléolipides
FR3078064A1 (fr) 2018-02-22 2019-08-23 Universite de Bordeaux Procede de decontamination d'un milieu liquide aqueux contenant des micropolluants
EP4013740B1 (fr) * 2019-08-12 2026-04-08 Integrated Nanotherapeutics Inc. Lipides pour l'administration d'un matériau chargé, leurs formulations et leur procédé de fabrication
EP4635967A1 (fr) * 2022-12-13 2025-10-22 Tuojie Biotech (Shanghai) Co., Ltd. Oligonucléotide comprenant un monomère lipophile et son utilisation dans le cadre d'une délivrance non hépatique
WO2024140624A1 (fr) * 2022-12-27 2024-07-04 Suzhou Abogen Biosciences Co., Ltd. Composés lipidiques et compositions de nanoparticules lipidiques
WO2024240125A1 (fr) * 2023-05-22 2024-11-28 Suzhou Abogen Biosciences Co., Ltd. Composés lipidiques et compositions de nanoparticules lipidiques

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0696590B2 (ja) * 1985-04-16 1994-11-30 富山化学工業株式会社 新規な５−フルオロ−２′−デオキシウリジン−３′−ホスフエ−ト誘導体およびその塩
DK86988A (da) * 1987-02-25 1988-08-26 Takeda Chemical Industries Ltd Liposompraeparat og anvendelse deraf
US6001817A (en) * 1998-01-12 1999-12-14 Unitech Pharmaceuticals, Inc. Pharmaceutical composition comprised of cisplatin, and processes for making and using same
GB9813535D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
AU2158401A (en) * 1999-11-05 2001-05-14 Seed Capital Investments-2 (Sci-2) B.V. Method for the formulation of substances having a low water-solubility and lipophilicity and formulation thus obtained
US20050070872A1 (en) * 2001-12-28 2005-03-31 Kenichi Sato Blood bag system and method of inactivating pathogenic microorganisms
FR2869616B1 (fr) * 2004-04-29 2008-10-24 Univ D Avignon Et Des Pays Du Nouveaux composes amphiphiles, leur procede de preparation et leurs applications notamment a la transfection
CA2609343C (fr) * 2005-06-07 2015-03-31 Yale University Procedes permettant de traiter le cancer et d'autres etats ou pathologies au moyen de lfmau et ldt
FR2945946B1 (fr) * 2009-05-29 2011-08-26 Univ Victor Segalen Bordeaux 2 Formulations a compartiments multiples a base de molecules ou macromolecules amphiphiles fonctionnelles

Also Published As

Publication number Publication date
JP2015044815A (ja) 2015-03-12
FR2924430B1 (fr) 2010-03-19
JP2017014243A (ja) 2017-01-19
WO2009098404A3 (fr) 2009-11-12
WO2009098404A2 (fr) 2009-08-13
JP5719594B2 (ja) 2015-05-20
JP2011504920A (ja) 2011-02-17
FR2924430A1 (fr) 2009-06-05
US20140308343A1 (en) 2014-10-16
CN101932310B (zh) 2013-11-13
JP6280167B2 (ja) 2018-02-14
US20110059180A1 (en) 2011-03-10
US9533049B2 (en) 2017-01-03
EP2231132A2 (fr) 2010-09-29
CA2706812A1 (fr) 2009-08-13
CN101932310A (zh) 2010-12-29

Similar Documents

Publication Publication Date Title
WO2009098404A3 (fr) Procédé de préparation de nanoparticules à base de molécules ou macromolécules amphiphiles fonctionnelles et leur utilisation
CY2015009I2 (el) Ινδολινονες υποκατεστημενες στη θεση 6, η παραγωγη αυτων και η χρηση αυτων ως φαρμακευτικα μεσα
WO2009120247A3 (fr) Compositions de nanoparticules de lipides et procédés de préparation et d’utilisation de celles-ci
PL2446904T3 (pl) Przeciwciała anty-CD22, ich immunokoniugaty oraz ich zastosowania
WO2010069532A8 (fr) Anticorps dirigés contre l'angiopoïétine 2 humaine
IL247486B (en) A composition comprising nanoparticles comprising docetaxel, albumin and citrate, uses thereof, a method for it's preparation and a sealed vial and a kit comprising the composition
WO2008030211A3 (fr) Procédés de fabrication d'une dispersion de nanomatériaux et produits issus de celle-ci
DK1943016T3 (da) Kompositnanopartikler, nanopartikler og fremgangsmåder til fremstilling heraf
WO2010013224A3 (fr) Nanoparticules de curcumine et leurs procédés de production
WO2007118653A3 (fr) Nanoparticules contenant de la nicotine et/ou de la cotinine, dispersions et leur utilisation
WO2008033300A3 (fr) Formulation de bis (thiohydrazide amides)
SI1909843T1 (sl) Protitumorski biokonjugati hialuronske kisline ali njenih derivatov, dobljeni z indirektno kemijsko konjugacijo, in njihova uporaba na farmacevtskem področju
WO2007047498A3 (fr) Formation et encapsulation de membranes moleculaires monocouches et bicouches
IL201730A (en) History 1h - Benzaimidazole – 2 – Il – Profile – Methyl – Amino – Ethyl – 5 – Aryl – Bicyclo [2.2.2] Oct – 5 – Ann – 2 – All, Pharmaceutical preparations containing them and their use in the preparation of drugs
EP2167083A4 (fr) Nouveaux 1- hétéroaryl-3-azabicycloý3.1.0¨hexanes, leurs méthodes de préparation et leur utilisation comme médicaments
SI2266619T1 (sl) Farmacevtski sestavek na osnovi hepatoprotektorja in prebiotika, njegova izdelava in uporaba
WO2008110374A3 (fr) Granulés contenant une substance pharmaceutique, procédés de fabrication et utilisation de ceux-ci
TW200637795A (en) Polyporous material having nanoparticle and their preparation
ZA201009097B (en) C-ring-substituted pregn-4-ene-21,17-carbolactone,and pharmaceutical preparations comprising the latter
ATE531715T1 (de) 1,3-dihydro-2h-pyrroloä3.2-büpyridin-2-onderiva e,deren herstellung und deren therapeutische verwendungen
SG148120A1 (en) An oral pharmaceutical and an oral care product
FR2895412B1 (fr) Procede de preparation de nanoparticules en feuillets et nanoparticules obtenues.
WO2009117185A3 (fr) Hydrogels non dégradables pour une application à des dispositifs médicaux
WO2007109152A3 (fr) Lipophiles à fonctionnalité amine/amide
WO2009001144A3 (fr) Compositions pharmaceutiques

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880126008.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08872219

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2706812

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010535425

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 4453/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008872219

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12745670

Country of ref document: US